Global biotechnology leader CSL recently celebrated the addition of Vifor Pharma and its portfolio of products in nephrology and rare disease, kidney dialysis and iron therapy.
“Together we are stronger, with complementary capabilities that enhance our global therapeutic positions, capacity for innovation, scale and growth potential,” CSL CEO and Managing Director Paul Perreault said of the acquisition finalized on August 9.
CSL, driven by its promise to patients and a commitment to public health, develops and manufactures treatments for people with rare and serious diseases, as well as influenza vaccines.
Here are three fast facts about CSL Vifor*, as it will be known – a name that honors its successful legacy:
- In addition to its portfolio of products, CSL Vifor has a proven strategy for partnering, business development and licensing, which will expand CSL’s presence in the rapidly growing nephrology market. For several years, CSL Behring has been researching potential medicines to prevent rejection in organ transplant patients.
- The addition of CSL Vifor employees brings CSL’s total employee count to 30,000. CSL Vifor employees work in several global locations and the business is based in Switzerland, with a large presence in Zurich and St. Gallen, home to a center of excellence in the manufacturing of supplemental iron. CSL recently named Hervé Gisserot, previously Vifor’s Chief Commercial Officer, as CSL Vifor’s General Manager.
- With this strategic move forward, CSL reaffirms its values and culture by coming together as one CSL dedicated to saving, improving and protecting life – and branding itself as such. In addition to CSL Vifor, the businesses of CSL now include CSL Behring, which develops and delivers medicines for patients who have primary immunodeficiency, hemophilia and other diseases; CSL Plasma, one of the world’s largest collectors of plasma used solely for the production of life-saving medicines; and CSL’s influenza vaccine business, CSL Seqirus*.
*CSL will follow the required legal processes of formally changing the names for Vifor Pharma and Seqirus entities in due course.